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The syndrome of severe, acute, intensive care unit (ICU)-
acquired neuromuscular weakness poses a common and
serious diagnostic, prognostic, and therefore management
issue. It goes by various names, some of which presuppose a
mechanism: acute necrotizing myopathy of intensive care,
acute quadriplegic myopathy, critical care myopathy, critical
illness myopathy (CIM), critical illness neuromuscular
disease, critical illness neuromyopathy, critical illness
polyneuromyopathy, critical illness polyneuropathy (CIP),
ICU-acquired paresis, quadriplegic and areflexic ICU illness,
rapidly evolving myopathy with myosin-deficient fibres and
thick filament myopathy [1–6]. The problem affects at least
1.7% of children in paediatric ICUs, more than half of adult
patients admitted to general ICUs for more than 1 week and
more than 70% of those with sepsis and multiorgan failure
[7–9]. Neuromuscular weakness typically becomes apparent
when an attempt is made to wean the patient from the
ventilator, although there are earlier clues, which include
grimacing without movement with noxious stimuli before
recovery of consciousness, relative lack of movement after
regaining consciousness, and (not inevitably) loss of deep
tendon reflexes that had been present earlier [10].
Precise diagnosis is vital for management. Although most
cases will turn out to be critical illness polyneuromyopathy
[11] – a term that embraces CIP, CIM, or a combination of
the two – other potential causes should not be overlooked. A
systematic approach is suggested in Fig. 1. The algorithm
illustrates the early ruling in or out of spinal cord disease (e.g.
in cases of trauma, coagulation disturbance, West Nile virus
infection, acute disseminated encephalomyelitis, etc.), and
then moving on to a clinical–biochemical–electromyographic
assessment. A neuromuscular transmission defect (e.g. slow
inactivation of neuromuscular blocking agents, unrecognized
myasthenia gravis, or myasthenic [Lambert–Eaton]
syndrome) is easily detected with repetitive nerve stimulation,
revealing either a decremental or incremental response.
Neuropathies other than CIP that may manifest after ICU
admission include Guillain–Barré syndrome/acute immune-
mediated demyelinating polyneuropathy (and its various
subtypes), porphyria and recurrent chronic inflammatory
demyelinating polyneuropathy. These are usually easily ruled
in or out. Demyelinating inflammatory neuropathies usually
cause slowing of conduction velocity and conduction block
on electromyographic studies and produce increased protein
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Abstract
ICU-acquired limb and respiratory muscle weakness is a common, serious ICU syndrome, increasing in
frequency with prolonged ICU stay and sepsis. A systematic approach facilitates precise localization of
the problem within central or peripheral nervous system. Most cases relate to critical illness
polyneuropathy or myopathy or a combination of both (critical illness neuromyopathy). Within the latter
entity, the relative contribution of neuropathy versus myopathy varies considerably among affected
patients. Muscle enzyme testing, electromyography-nerve conduction and muscle biopsy are valuable
investigative tests. Nerve biopsy is less commonly needed, but is useful when vascultis is suspected.
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in the cerebrospinal fluid. Biochemical screening for
porphyria during acute attacks should be positive. Other
conditions, such as inflammatory myopathies or unrecognized
motor neurone disease, are not discussed here because they
are usually diagnosed before admission to ICU, although they
sometimes present with respiratory weakness that requires
ICU admission.
The last step, differentiating the most common causes of ICU-
acquired generalized weakness (myopathy, neuropathy, or a
combination of the two), is practical because their prognoses
differ considerably. Some cases of myopathy appear to be
merely ‘membranopathies’, with normal histology and rapid
recovery. Presumably, the muscle membrane becomes
dysfunctional, inexcitable and leaky, allowing myoglobin to
leave the muscle. Some cases behave like disuse atrophy with
selective type-2 fibre loss. Others, especially in those treated
with corticosteroids and neuromuscular blocking agents,
exhibit a relative loss of thick myosin filaments. Many cases
show variable panfascicular necrosis, which can sometimes
be widespread and severe. In general, the prognosis for
recovery from myopathies is favourable, with most patients
recovering fully within 1–3 months [6]. Patients with
widespread muscle necrosis may recover incompletely,
however. Severe CIP patients recover slowly because the
axons regenerate at 1 mm/day. This takes many months and
recovery is often incomplete, leaving patients with significant
weakness, sensory loss, and absent reflexes distally in the
Figure 1
A flow chart giving an approach to generalized weakness and/or ventilatory failure in the intensive care unit. CK, creatine kinase; CSF,
cerebrospinal fluid; GBS, Guillain–Barré syndrome; EMG, electromyography; MRI, magnetic resonance imaging; LEMS, Lambert–Eaton
(myasthenic) syndrome; MG, myasthenia gravis; NCV, nerve conduction velocity studies; N-M, neuromuscular transmission; SNAPs, sensory nerve
action potentials. Modified from Bolton and Young [16].
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lower limbs and variably more proximally. Patients with CIP
who fail to show significant recovery by 4 weeks are often
disabled with diminished quality of life [8]. Evidence of
polyneuropathy is apparent after 5 years in over 90% of CIP
patients [12]. The mildest residua may include reduced
stamina for walking. Some older patients may fail to survive or
wean from the ventilator because their recovery is so
protracted and other complications ensue.
Electromyography is helpful in differentiating CIP from CIM
but it has limitations [13]. Reduced or absent sensory nerve
action potentials favours a neuropathy, but sensory potentials
may be difficult to record if there is considerable oedema or a
pre-existing polyneuropathy (e.g. from diabetes mellitus) may
have clouded the issue. Direct muscle stimulation (not
commonly done) may reveal no or absent response in CIM
but normal responses in CIP [14]. Unfortunately, needle
electrode studies of muscle can show similar features in CIP
and CIM; both may exhibit spontaneous activity (fibrillations
and positive sharp waves). Often CIP and CIM coexist and
their relative contributions to the weakness may vary
considerably when this occurs. Elevated serum creatine
kinase may help to identify CIM, but the peak may be missed
in the membranopathy/necrotizing varieties or creatine kinase
may not be significantly elevated in cases with loss of myosin
filaments. To determine the relative contributions of nerve
versus muscle disease in explaining weakness, muscle or
both nerve and muscle biopsies have been utilized and
recommended [11], most recently in this issue by Kerbaul
and colleagues [15]. In most cases muscle biopsy will
address the relative contribution of myopathy to the picture
because the neuropathy can be adequately assessed
electrophysiologically. Percutaneous muscle biopsy, although
providing limited tissue, has a number of advantages over
operative biopsies: greater spatial sampling, minimal
bleeding, negligible infection rate (we have had none in over
1000 biopsies), portability (done at the bedside), no general
anaesthetic, speed of performance and ease of arrangement.
Nerve and muscle biopsy is seldom necessary in the ICU,
unless a vasculitis is suspected. An open muscle biopsy may
also be necessary if the needle biopsies are inadequate.
Being aware of the incidence and signs of ICU-acquired
weakness with ventilatory failure and having an approach to
such disorders will prove valuable in management. Some
conditions are treatable. Further insights into the mechanisms
of CIP and CIM may provide some preventive strategies that
will ameliorate their severity, shorten the duration of ICU
stays and improve long-term outcomes.
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